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Despite significant improvement in recent ther-
apeutic technologies, >90% of the cancer deaths 
are still attributed to metastatic disease (Peinado 
et al., 2008). In the case of prostate and breast 
cancers, 20–50% patients who have localized can-
cer and have been “successfully” treated with sur-
gery eventually experience recurrent disease after 
many years (Karrison et al., 1999; Weckermann 
et al., 2001; Pfitzenmaier et al., 2006). How 
metastatic tumor cells become dormant in the 
distant organs is virtually unknown. However, 
because recurrent disease is almost always fatal, 
it is of paramount importance to elucidate the 
underlying molecular mechanism of dormancy 
and recurrence to identify novel therapeutic tar-
gets. The dormant state of metastatic cell is 
thought to be controlled by both genetic changes 
in  tumor  cell  and  microenvironment  of  the 
metastasized  organs  (Aguirre-Ghiso,  2007).   
According to the recent tumor stem cell theory, 
metastatic cells must have stem-like characteristics 
such as abilities of self-renewal and differentiation 
in addition to their invasive capability (Pantel   
and Alix-Panabières, 2007; Polyak and Weinberg, 
2009). Therefore,  only  a  fraction  of  primary   
tumor cells is able to establish colonization at 
the  distant  organ  and  also  become  dormant. 
However, because dormant lesions in most cases 
consist of a solitary or small number of tumor 
cells, they are clinically undetectable, which sig-
nificantly hampers the progress of research in 
this field. This dormant state is thought to be 
maintained  by  virtue  of  the  balance  of  local   
microenvironment such as stroma–tumor cell 
interaction and secreted growth factors and pro- 
and antiangiogenic factors, as well as local im-
mune system (Derynck et al., 2001; Bhowmick 
et al., 2004; Aguirre-Ghiso, 2007). The most 
critical question is to identify such key players 
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Metastatic disease is the major cause of cancer deaths, and recurrent tumors at distant 
organs are a critical issue. However, how metastatic tumor cells become dormant and how 
and why tumors recur in target organs are not well understood. In this study, we demon-
strate that BMP7 (bone morphogenetic protein 7) secreted from bone stromal cells induces 
senescence in prostate cancer stem-like cells (CSCs) by activating p38 mitogen-activated 
protein kinase and increasing expression of the cell cycle inhibitor, p21, and the metastasis 
suppressor gene, NDRG1 (N-myc downstream-regulated gene 1). This effect of BMP7 
depended on BMPR2 (BMP receptor 2), and BMPR2 expression inversely correlated with 
recurrence and bone metastasis in prostate cancer patients. Importantly, this BMP7- 
induced senescence in CSCs was reversible upon withdrawal of BMP7. Furthermore, treat-
ment of mice with BMP7 significantly suppressed the growth of CSCs in bone, whereas  
the withdrawal of BMP7 restarted growth of these cells. These results suggest that the 
BMP7–BMPR2–p38–NDRG1 axis plays a critical role in dormancy and recurrence of pros-
tate CSCs in bone and suggest a potential therapeutic utility of BMP7 for recurrent meta-
static disease.
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Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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secreted from bone stromal cells, induces senescence through 
activation of p38 MAPK, cell cycle inhibitor, p21, and the   
tumor metastasis suppressor gene, NDRG1 (N-myc downstream-
regulated gene 1) in prostate cancer stem-like cells (CSCs). Im-
portantly, this BMP7-induced senescence was found to be 
reversible, indicating that BMP7 plays a critical role in tumor 
dormancy and recurrence. Our results also suggest that target-
ing BMP7 signaling may become effective therapeutics to pre-
vent recurrence of metastatic prostate cancer.
RESULTS
A secretory factor from bone stromal cells suppresses  
the growth of prostate cancer cells
Bone stromal cells are considered to play a critical role in gen-
erating a niche for metastasized tumor cells by secreting various 
growth-inhibitory as well as growth-promoting factors in the 
microenvironment, which may contribute to tumor dormancy 
and recurrence (McAllister et al., 2008; Zhang et al., 2009). In 
an attempt to identify such factors, we first cultured PC3 mm, 
a metastatic prostate cancer cell line, in the presence of the 
conditioned medium (CM) of human BM stromal cells (HS5). 
We found that the CM of HS5 significantly promoted the 
expression  of  the  key  cell  cycle  inhibitors,  p21  and  p27   
(Fig. 1 A). The up-regulation of p21 by the CM of HS5 was 
also observed in a panel of prostate cancer cell lines (Fig. 1 B). 
that modulate the tumor cell dormancy and to dissect the re-
sponsive signaling pathways.
Recently, others demonstrated, through a series of elegant 
experiments, that the signaling cascade that is controlled by the 
balance of two prominent pathways, p38 mitogen-activated 
protein kinase (MAPK) and extracellular signal-regulated 
kinase (ERK), is the key determining factor for tumor cell dor-
mancy (Aguirre-Ghiso et al., 2001, 2003, 2004; Aguirre-Ghiso, 
2007). p38 signaling is also known to be involved in the regu-
lation of cell cycle arrest and plays a crucial role in the induc-
tion of senescence in response to a variety of stress, including 
oncogenic stress (Bulavin and Fornace, 2004; Bulavin et al., 
2004; Dasari et al., 2006; Tront et al., 2006; Han and Sun, 
2007; Sun et al., 2007; Wagner and Nebreda, 2009). A high 
ratio of ERK/p38 expression was indeed observed in meta-
static lesions in an animal model of ovarian cancer, which 
supports the notion that the balance of ERK and p38 deter-
mines the fate of disseminated tumor cells whether to prolifer-
ate or stay in dormant state at the distant organ (Aguirre-Ghiso 
et al., 2004). However, extracellular factors in the microenvi-
ronment, either cell–cell interaction or secretory factors, that 
regulate p38 signaling and modulate the concomitant tumor 
cell dormancy and recurrence are yet to be determined.
In this study, we found that one of the TGF- family 
members, BMP7 (bone morphogenetic protein 7), which is 
Figure 1.  CM of bone stromal cells in-
duces senescence in prostate cancer cells. 
(A) The prostate cancer cell line PC3 mm was 
cultured in the presence of CM from human 
bone stromal cells (HS5), mouse BM stroma 
(MBMS), mouse embryonic fibroblasts 
(NIH3T3), or human lung fibroblasts (MRC5) 
or serum-free medium (). Expression of p21, 
p27, and -tubulin was examined by qRT-PCR 
(n = 3) and Western blot. (B) The prostate 
tumor cell lines LNCaP, C4, C4-2, C4-2B, PC3, 
DU145, and ALVA were cultured in the pres-
ence of CM of HS5 or serum-free medium (), 
and the expression of p21 was examined  
by qRT-PCR (n = 3). (C) PC3 mm was cultured 
in the presence of CM of HS5, MBMS, NIH3T3, 
or MRC5 or serum-free medium (), and the 
activation of p38 (phosphorylated p38, p-p38; 
total p38, p38) and the expression of NDRG1 
and -tubulin were examined by Western 
blot. (D) LNCaP, C4, C4-2, C4-2B, PC3, ALVA, 
and DU145 were cultured in the presence or 
absence of CM of HS5, and the expression of 
p-p38, p38, and -tubulin was examined by 
Western blot. (E) PC3 mm was cultured in the 
presence or absence of CM of HS5 or MRC5 
for 48 h, and cell viability was measured by 
the MTT assay (n = 3). (F) PC3 mm was cul-
tured in the presence or absence of HS5-CM 
for 48 h, and SA–-gal staining (blue-green) was performed (n = 4). The inset shows representative images of three independent experiments. Bar, 100 µm.  
(G) PC3 mm was cultured in the presence of CM of HS5, MRC5, or NIH3T3 or serum-free medium (), and the expression of NDRG1 was measured by 
qRT-PCR (n = 3). *, P < 0.05; **, P < 0.01; ***, P < 0.001. All experiments were performed three times independently, and representative data are shown. 
Results are shown as mean ± SEM.JEM Vol. 208, No. 13 
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cancers (Fig. 1, C and G; Guan et al., 2000; Bandyopadhyay   
et al., 2003, 2004). It should be noted that we previously 
showed a significant inverse correlation between NDRG1 
expression  and  bone  metastasis  in  prostate  cancer  patients   
(Bandyopadhyay et al., 2003). These results strongly suggest 
that a secretory factor of bone stromal cells induces cellular   
senescence by activating p38, NDRG1, and cell cycle inhibi-
tors in tumor cells.
BMP7 up-regulates a metastasis suppressor gene, NDRG1, 
through activation of p38
The next critical question is the identity of the secretory fac-
tor from bone stromal cell. Because TGF- (Mundy, 2002; 
Massagué,  2008)  and  TGF-  family  members,   
BMPs  (Celeste  et  al.,  1990;  Mundy,  2002)  and 
FGF2 (fibroblast growth factor 2; Johnson et al., 
1998;  Mundy,  2002;  Korah  et  al.,  2004),  are  all 
known to exist in the bone microenvironment,   
we first examined the effect of a selective inhibitor 
of TGF- type 1 receptor, SB431542, and a gen-
eral BMP inhibitor, Noggin, on the activation of 
NDRG1  and  p38. The  addition  of  Noggin  to 
HS5-CM in our assay system significantly blocked 
the  ability  of  CM  to  activate  NDRG1  and  p38, 
whereas SB431542 did not affect the CM-induced 
p38 activation,  and  recombinant  human TGF- 
failed to activate NDRG1 (Fig. 2 A and not depicted). 
Moreover, p38 MAPK, which has been shown to be a key 
regulator of tumor cell dormancy (Aguirre-Ghiso, 2007), was 
strongly activated in prostate cancer cell lines in the presence 
of the CM of bone stromal cells (Fig. 1, C and D). In fact, we 
found  that  the  CM  of  HS5  significantly  suppressed  the 
growth of prostate cancer cell lines (Fig. 1 E and not depicted) 
and  induced  senescence-associated  -galactosidase  (SA– 
-gal) activity (Fig. 1 F) but not apoptosis of PC3 mm cells 
(not depicted), suggesting that the bone stromal cells secrete a 
growth-inhibitory factor. Interestingly, we also found that the 
CM of bone stromal cells significantly up-regulated the meta-
stasis suppressor gene, NDRG1, which was previously shown 
to suppress tumor metastasis in prostate, breast, and colon 
Figure 2.  BMP7 up-regulates NDRG1 through activa-
tion of p38. (A) PC3 mm cells were grown in the presence of 
HS5-CM with 3 µg/ml BMP inhibitor Noggin (+) or vehicle (), 
and the expression of NDRG1, p-p38, p38, and -tubulin was 
examined by Western blot and qRT-PCR (n = 3; *, P < 0.05 vs. 
first bar; #, P < 0.05 vs. second bar). (B) The effect of BMP2, 
BMP4, BMP5, BMP6, BMP7, and FGF2 on the expression of  
p-p38, p38, p21, p27, NDRG1, and -tubulin in PC3 mm and 
DU145 cells was examined by Western blot. (C) LNCaP, C4, C4-2, 
C4-2B, and ALVA were cultured with or without 200 ng/ml 
BMP7, and the expression of p-p38, p38, and -tubulin was 
examined by Western blot. (D) The effect of the indicated con-
centrations of BMP7 on NDRG1 expression in PC3 mm and 
DU145 was examined by qRT-PCR (n = 3; *, P < 0.05). (E) The 
effect of the indicated concentrations of BMP7 on the expres-
sion of NDRG1 in PC3 mm was examined by NDRG1 reporter 
assay (n = 3; **, P < 0.01; ***, P < 0.001). (F and G) Western 
blot for BMP7 in the CM from bone stromal cells (hBMSC, 
hFOB1.19, and HS5) and prostate cancer cells (PC3 mm, 
DU145, C4-2B, and ALVA; F) or CM from HS5 that had either 
scrambled shRNA (scramble) or shRNA for BMP7 (shBMP7; G). 
(H) PC3 mm cells were cultured with the CM from HS5/scramble 
or HS5/shBMP7, and the expression of p-p38, NDRG1, p21, 
and -tubulin was examined by Western blot. (I and J) PC3 
mm cells were treated with or without 200 ng/ml BMP7 in the 
presence or absence of 10 µM of the p38 inhibitor SB203580 
(SB), and the expression of NDRG1 was examined by qRT-PCR 
(I) and by NDRG1 reporter assay (J; n = 3; *, P < 0.05; **, P < 
0.01; ***, P < 0.001). All experiments were performed three 
times independently, and representative data are shown.  
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senescence and p21 expression (Fig. 3, A–C). Although this 
activation of p21 by BMP7 was not affected by dominant-
negative Smad4 (Fig. 3 D), it was significantly suppressed by the 
p38 inhibitor (Fig. 3 E), suggesting that BMP7 up-regulates 
p21 through a non-Smad pathway. Furthermore, knock-
down of p21 in PC3 mm cells abrogated BMP7-induced 
NDRG1 expression, whereas the status of phospho-p38 was 
not affected by p21 knockdown (Fig. 3 F), implying that 
BMP7 up-regulates NDRG1 through the activation of p38 
and p21. Therefore, these results strongly suggest that the 
BMP7–p38–p21–NDRG1 axis plays a key role in tumor cell 
dormancy in the bone.
To gain further insight into BMP7-mediated cell growth 
arrest, we incubated PC3 mm cells with BMP7 for 8 d fol-
lowed by withdrawal of this factor. BMP7 significantly sup-
pressed the cell growth; however, cells regained the ability to 
grow upon withdrawal of BMP7 (Fig. 4 A). We also exam-
ined the effect of BMP7 withdrawal on Erk activity. In this 
experiment, epidermal growth factor (EGF) was used as an acti-
vator of Erk. We found that the phosphorylation of Erk was 
greatly suppressed in the presence of BMP7, whereas p38 phos-
phorylation was strongly enhanced (Fig. 4 B). Interestingly, 
withdrawal of BMP7 restored the Erk phosphorylation, whereas 
it reversed the phosphorylation of p38, suggesting that the 
p38/Erk ratio plays an important role in determining whether 
the tumor cells stay in dormant state or proliferate. Further-
more, we tested this reversibility of the BMP7 effect on senes-
cence by SA–-gal staining. PC3 mm cells were cultured with 
BMP7 for 48 h, and then they were incubated another 48 h 
either  with  (+/+)   
or  without  (+/) 
BMP7.  We  found 
that BMP7 treatment 
(+/+) significantly 
increased  senescent 
cells compared with 
We then directly tested the effect of purified BMPs as well as 
FGF2 using both PC3 mm and DU145 cells and found that 
only BMP7 among these factors was able to activate all of p38, 
NDRG1, p21, and p27 (Fig. 2 B). The activation of p38 was 
also observed in a panel of prostate cancer cell lines (Fig. 2 C). 
Moreover,  BMP7  significantly  up-regulated  the  NDRG1 
messenger RNA expression and promoter activity in a dose-
dependent manner (Fig. 2, D and E). Furthermore, our results 
of Western blot analysis demonstrate that BMP7 is expressed at 
a much higher level in HS5 as well as other bone stromal cells 
including human BM-derived mesenchymal stem cells (MSCs 
[hBMSCs]) and human osteoblast cells (hFOB1.19) than in the 
prostate cancer cells (Fig. 2 F). These results suggest that the 
major sources of BMP7 at the metastatic sites are various 
bone stromal cells rather than cancer cells per se. To further ver-
ify that BMP7 secreted in CM was responsible for the activation 
of these molecules, we silenced the BMP7 gene in HS5 by short 
hairpin RNA (shRNA; Fig. 2 G). Indeed, CM of BMP7–
knocked down HS5 failed to activate p38, NDRG1, and p21, 
whereas CM of control HS5 strongly stimulated all three   
proteins (Fig. 2 H). We also found that the activation of NDRG1 
by  BMP7  was  significantly  blocked  by  the  p38  inhibitor, 
SB203580, suggesting that BMP7 up-regulates NDRG1 through 
activation of the p38 pathway (Fig. 2, I and J).
BMP7 induces reversible senescence through activation  
of p38, p21, and NDRG1
BMP7 was originally identified as an osteoinductive factor 
from bone (Celeste et al., 1990; Ozkaynak et al., 1990), and 
it has been shown to be involved in normal bone morpho-
genesis and to play an important role in bone regeneration 
(Dudley et al., 1995; Luo et al., 1995; Friedlaender et al., 
2001; Ristiniemi et al., 2007). To further assess the growth 
inhibitory effect of BMP7 on tumor cells, we measured   
SA–-gal activity in prostate cancer cells and found that 
BMP7 indeed induced growth arrest with features of cellular 
Figure 3.  BMP7 up-regulates NDRG1 by 
activating p38 and p21. (A) Effect of  
200 ng/ml BMP7 on senescence in PC3 mm 
was examined by SA–-gal staining (n = 4). ,  
control vehicle. The inset shows representa-
tive images of three independent experiments. 
Bar, 100 µm. (B and C) Effect of 200 ng/ml 
BMP7 on p21 was measured by qRT-PCR and 
p21 reporter assay in PC3 mm (B and C) and 
DU145, C4, C4-2, and C4-2B cells (B; n = 3). 
Control, control vehicle. (D) PC3 mm cells 
were transiently transfected with dominant-
negative Smad4 (DN-Smad4) or empty vector 
and then cultured with or without BMP7 for 
48 h. Expression of p21 was assessed by qRT-
PCR (n = 3). (E) PC3 mm cells were treated 
with or without 200 ng/ml BMP7 and/or 10 µM 
SB203580 (SB), and the expression of p21  
was examined by qRT-PCR (n = 3). (F) PC3 
mm cells that had either scrambled shRNA 
(scramble) or shRNA for p21 (shp21) were 
treated with or without BMP7, and the ex-
pression of p-p38, p38, p21, NDRG1, and  
-tubulin was examined by Western blot.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001. All  
experiments were performed three times  
independently, and representative data are 
shown. Results are shown as mean ± SEM.JEM Vol. 208, No. 13 
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Figure 4.  BMP7 induces reversible senescence. (A) Effect of BMP7 on the growth of PC3 mm cells was measured by the MTT assay. Cells were 
treated with 200 ng/ml BMP7 continuously (green), with BMP7 between day 4 and 11 followed by BMP7 withdrawal (red), or with control vehicle (black; 
n = 5). (B) PC3 mm cells were cultured with 10 ng/ml EGF or 200 ng/ml BMP7 alone, or EGF with BMP7, or EGF with BMP7 followed by BMP7 withdrawal, 
and the expression of p-Erk, Erk, p-p38, p38, and -tubulin was examined by Western blot. (C) Effect of BMP7 on growth arrest was examined by SA–-gal 
staining (top) and cell cycle analysis (bottom). PC3 mm cells (left) and C4-2B cells (right) were cultured with (+/+) or without (/) BMP7 for 96 h.  
+/ cells were treated with BMP7 for 48 h followed by withdrawal of BMP7 and further incubation for 48 h (n = 3). (D) Effect of BMP7 on senescence 
was examined by SA–-gal staining. DU145, LNCaP, C4, and ALVA were cultured with (+/+) or without (/) BMP7 for 96 h. +/ cells were treated with 
BMP7 for 48 h followed by withdrawal of BMP7 and further incubation for 48 h (n = 3). (C and D) The insets show representative images of three inde-
pendent experiments. Bars, 50 µm. (E and F) PC3 mm cells that had either scrambled shRNA (scramble) or shRNA for NDRG1 (shNDRG1) were cultured 
with BMP7 or control vehicle, and the knockdown of NDRG1 was confirmed by qRT-PCR (n = 3; E). These cells were stained for SA–-gal activity (n = 4; F). 
(G) Effect of NDRG1 on senescence was examined by SA–-gal staining (bottom). PC3 mm cells stably expressing Tet-NDRG1 were cultured with (+/+) or 
without (/) tetracycline for 96- or 48-h treatment followed by 48-h withdrawal of tetracycline (+/; n = 4). The expression of NDRG1 and -tubulin 
was examined by Western blot (top). *, P < 0.05; **, P < 0.01; ***, P < 0.001. The experiment in A was performed twice, experiments in B–G were performed 
three times independently, and representative data are shown. Results are shown as mean ± SEM.2646 BMP7 in prostate cancer dormancy and recurrence | Kobayashi et al.
Figure 5.  The expression of BMPR2 receptor 
is inversely correlated with recurrence and 
bone metastasis of prostate cancer patients. 
(A) The relation between recurrence-free survival 
and the expression (positive or negative) of the 
indicated BMP receptors was analyzed using an 
existing cohort data of prostate cancer patients 
(n = 21; Glinsky et al., 2004). *, P = 0.0485 (Log-
rank test). (B, top) Representative images of  
immunohistochemical staining for BMPR2 on 
prostate cancer patient samples with or without 
bone metastasis. Bar, 50 µm. (bottom) The cor-
relation between BMPR2 expression and bone 
metastasis (met) status was evaluated by Fisher’s 
exact test.
significantly reversed this effect (Fig. 4 G). 
These results suggest that BMP7 induces 
reversible senescence in prostate cancer 
cells and that this effect is indeed medi-
ated by NDRG1.
BMP receptor, BMPR2, has an inverse 
correlation with bone metastasis  
and recurrence
The results of our in vitro experiments 
suggest that BMP7-induced reversible se-
nescence contributes to tumor dormancy 
and recurrence in bone environment. Therefore, we exam-
ined the possibility that the status of BMP receptors in pa-
tients is a determining factor in bone metastasis and recurrence 
of prostate cancer. To test this hypothesis, we first analyzed 
the expression profile of the BMP receptors in prostate can-
cer patients and their clinical status using the existing database 
(http://www-genome.wi.mit.edu/cancer/; Glinsky et al., 
2004). Among these receptors, the expression of BMPR2 had 
significant positive correlation with the recurrence-free sur-
vival of patients (Fig. 5 A). To further investigate the role of 
BMPR2 in prostate cancer and its clinical relevance to bone 
metastasis, we performed immunohistochemical analysis for 
BMPR2 with a prostate tissue array that contains 41 primary 
prostate cancer samples. Consistently, there was a significant 
inverse correlation between BMPR2 expression and bone 
metastasis of prostate cancer patients (Fig. 5 B), suggesting 
that BMPR2 plays a critical role in tumor dormancy and re-
currence in bone metastasis. To directly address this question, 
we first examined the status of BMPR2 expression in our ex-
perimental metastasis model in vivo. We isolated cancer cells 
from micrometastases in tibiae of mice after implanting PC3 
mm cells through intracardiac injection. We then examined 
the expression of BMPR2 in these cells by Western blot and 
found that a comparable level of BMPR2 expression to the 
parental cells was maintained in these cells (not depicted). 
Next, we asked whether knockdown of BMPR2 can abro-
gate the BMP7-induced dormancy in bone metastasis. To 
this end, mice were inoculated with PC3 mm cells that had 
either shRNA for BMPR2 (shBMPR2) or scrambled shRNA 
control (/) cells that were cultured in the absence of 
BMP7 throughout the period (Fig. 4 C, left). To our sur-
prise, withdrawal of BMP7 (+/) significantly reduced the 
senescent cells to the control level, suggesting that BMP7- 
induced senescence is reversible. In support of this observa-
tion, we performed cell cycle analysis and found that the 
BMP7 treatment (+/+) significantly increased the fraction of 
cells in the G1 phase compared with the control (/), 
whereas withdrawal of BMP7 (+/) significantly decreased 
the cell population in the G1 state, suggesting that BMP7 in-
duced G1 arrest in PC3 mm cells. We also observed the re-
versible senescence phenotype upon withdrawal of BMP7   
in other prostate cancer cell lines (Fig. 4, C [right] and D). 
Among the cell lines we tested in these experiments, PC3 mm 
and DU145 are androgen receptor (AR) negative, whereas 
LNCaP, C4, C4-2B, and ALVA are AR positive. Interest-
ingly, the reversible senescence phenotype was observed in 
both  AR-negative  and  -positive  cells,  suggesting  that  the   
effect of BMP7 on recurrent growth is independent of the 
AR status of the cells. We then examined whether NDRG1, 
a downstream effector of BMP7 signaling, also plays a role in 
the induction of senescence in prostate cancer cells. When 
NDRG1 expression was knocked down by shRNA in PC3 
mm (Fig. 4 E), the cells failed to enter senescence even in the 
presence of BMP7 (Fig. 4 F). In contrast, up-regulation of 
NDRG1 by adding tetracycline for a total of 96 h (+/+) to the 
PC3  mm  cell  line,  which  had  the  tetracycline-inducible 
NDRG1, significantly induced senescence; however, the 48-h 
withdrawal  of  tetracycline  (+/)  after  48-h  incubation JEM Vol. 208, No. 13 
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significantly decreased the senescent cells even in the pres-
ence of BMP7 (Tet+/+, BMP7), whereas the withdrawal of 
tetracycline (i.e., the recovery of BMPR2 expression) ame-
liorated the effect of BMP7 on the induction of senescence 
(Tet+/, BMP7; Fig. 6 D). Collectively, these results sug-
gest that BMPR2 is a critical mediator of BMP7 signaling for 
tumor cell dormancy in bone metastasis.
BMP7 suppresses the growth of CSCs
According to the cancer stem cell theory, a dormant and re-
current tumor cell must retain stem cell–like properties (Pantel 
and  Alix-Panabières,  2007;  Polyak  and  Weinberg,  2009). 
Therefore, we intended to examine the effect of BMP7 on 
CSCs. We first isolated the CSC population (CD24/CD44+/ 
CD133+) from PC3 mm cells that were labeled with the   
luciferase gene. Our result of serial dilution assay for tumor- 
initiating ability in animals indicates that the CSC population 
was  significantly  more  tumorigenic  than  non-stem  cells 
(CD24+/CD44/CD133; Fig. 7 A). We also found that 
BMP7 was able to activate p38, NDRG1, and p21 (Fig. 7, 
B–D) and that the induction of NDRG1 and p21 was medi-
ated by p38 (Fig. 7, C and D) in the CSCs. In addition, 
BMP7 significantly inhibited the sphere-forming ability of 
CSCs; however, these cells regained the growth ability after 
withdrawal of BMP7 from the medium (Fig. 7 E). Further-
more, we found that BMP7 was also able to induce senes-
cence in CSCs (Fig. 7 F, +/+) with concomitant activation 
of NDRG1 and p21 (Fig. 7, G and H, +/+). Of note, the 
BMP7-mediated induction of senescence as well as the acti-
vation of NDRG1 and p21 was reversed after withdrawal   
of BMP7 (Fig. 7, F–H, +/). Similarly, up-regulation of 
NDRG1 in CSCs significantly suppressed the sphere for-
mation  and  induced  senescence,  whereas  de-induction  of 
NDRG1 by withdrawal of tetracycline reversed this effect 
(Fig. 7, I and J). These results suggest that BMP7 was also 
able to induce reversible senescence in CSCs through activa-
tion of p38, p21, and NDRG1.
BMP7 suppresses the growth of CSCs in a reversible  
manner in vivo
Our results strongly support a notion that BMP7 secreted 
from bone stromal cells plays a role in tumor dormancy by 
suppressing the growth of CSCs in the bone environment. 
To determine whether the BMP7 from bone stromal cells 
indeed induces tumor growth arrest and senescence in vivo, 
we next used an animal model of bone metastasis. CSCs that 
were labeled with luciferase were isolated and injected into 
tibiae  of  mice  with  HS5  cells  that  had  either  scrambled 
shRNA (control) or shRNA for BMP7 (shBMP7). We found 
that the control HS5 was able to suppress tumor growth 
and activated p38 and NDRG1; however, HS5 with shBMP7 
significantly abrogated such an effect on CSCs and failed   
to suppress tumor-induced osteolysis in the tibiae (Fig. 8 A). 
These results suggest that BMP7 secreted from the bone 
stromal cells is indeed capable of inducing growth arrest of 
CSCs through activation of p38 and NDRG1 in the bone 
(control;  Fig.  6  A)  by  intracardiac  injection  followed  by 
BMP7 treatment. The progression of bone metastasis was 
monitored by bioluminescence imaging (BLI) using stably 
expressed luciferase reporter. We found that the BMP7 treat-
ment significantly delayed the onset of bone metastasis of 
the control group; however, the knockdown of BMPR2 
significantly attenuated the effect of BMP7 (Fig. 6 B). These 
results suggest that BMPR2 plays a direct role in BMP7-
induced  suppression  of  bone  metastasis. We  also  con-
firmed that BMPR2 knockdown disrupted BMP7 signaling   
in vitro. As shown in Fig. 6 C, BMPR2 deficiency strongly   
abrogated activation of p38, NDRG1, and p21 by BMP7. 
Furthermore, by using a cell line with tetracycline-inducible 
shBMPR2,  we  found  that  the  knockdown  of  BMPR2   
Figure 6.  BMPR2 mediates BMP7-induced reversible senescence. 
(A) The expression of BMPR2 and -tubulin in PC3 mm that had either 
scrambled shRNA (scramble) or shRNA for BMPR2 (shBMPR2) was ex-
amined by Western blot (top) and qRT-PCR (bottom; n = 3). (B) Kaplan-
Meier analysis for bone metastasis–free survival of mice after 
intracardiac injection of PC3 mm cells that carried either scrambled 
shRNA (scramble; n = 9) or shRNA for BMPR2 (shBMPR2; n = 10) fol-
lowed by treatment with vehicle or BMP7. Scramble versus Scramble + 
BMP7: ***, P < 0.0001; shBMPR2 versus shBMPR2 + BMP7: NS; Scram-
ble + BMP7 versus shBMPR2 + BMP7: ***, P = 0.0002 by Log-rank test. 
(C) PC3 mm/scramble cells and PC3 mm/shBMPR2 cells were treated 
with or without BMP7, and the expression of p-p38, p38, p21, NDRG1, 
and -tubulin was examined by Western blot. (D) The PC3 mm cells 
stably expressing Tet-shBMPR2 were cultured with (+) or without () 
induction of shBMPR2 in the presence or absence of BMP7, followed by 
assaying SA–-gal. /, no induction; +/+, continuous induction;  
+/, 48-h induction followed by 48-h withdrawal of tetracycline (n = 3).  
***, P < 0.001. The expression of BMPR2 and -tubulin was examined by 
Western blot (inset). Experiments in A, C, and D were performed three 
times, the experiment in B was performed twice independently, and 
representative data are shown. Results are shown as mean ± SEM.2648 BMP7 in prostate cancer dormancy and recurrence | Kobayashi et al.
of  using  BMP7  for  therapy  of  bone  metastatic  disease,   
100 µg/kg BMP7 was administrated daily i.v. after intracar-
diac injection of CSCs from PC3 mm or C4-2B cells to   
the mice. As shown in Fig. 8 C, BMP7 treatment signifi-
cantly  suppressed  the  bone  metastasis  compared  with  the 
control. Importantly, withdrawal of BMP7 treatment signifi-
cantly abrogated its suppressive effect and induced recurrent 
metastatic growth in the bones. To ensure the responsiveness 
of tumors derived from CSCs to BMP7, we also examined 
the effect of BMP7 on bone derivatives that were isolated 
from mice tibiae and found that BMP7 was indeed able to in-
duce reversible senescence in these bone derivatives (Fig. 8 D). 
These results suggest that BMP7 suppresses bone metastasis 
by inducing senescence in disseminated CSCs in the bone. 
environment. We also assessed the effect of NDRG1 in the 
suppression of tumor growth by coinjecting HS5 and CSCs 
in which NDRG1 expression was knocked down by shRNA 
(shNDRG1) into mice tibiae. We found that knockdown of 
NDRG1 in CSCs enabled these cells to grow significantly 
greater than that of control CSCs even when they were co-
injected with HS5 (Fig. 8 B). These results indicate that the 
BMP7–NDRG1 axis plays a critical role in the growth sup-
pression of metastasized prostate tumor cells in bone and 
also strongly suggest the potential therapeutic utility of BMP7 
for metastatic disease. It is noted that BMP7 is currently   
FDA approved for healing bone fractures after surgery with-
out having apparent adverse effect (Friedlaender et al., 2001; 
Ristiniemi et al., 2007). To directly address the possibility 
Figure 7.  BMP7 induces reversible senescence in CSCs through activation of p38, p21, and NDRG1. (A) CSCs isolated from PC3 mm were in-
jected subcutaneously into nude mice, and the growth of tumors was monitored by BLI. (B) The CSCs were treated with the HS5-CM or BMP7, and the 
expression of p-p38, NDRG1, and -tubulin was examined by Western blot. (C and D) The CSCs were treated with or without BMP7 and/or SB203580 (SB), 
and the expression of NDRG1 (C) and p21 (D) was examined by qRT-PCR (n = 3). *, P < 0.05; ***, P < 0.001. (E) Effect of BMP7 on the sphere forming abil-
ity of CSCs was measured. //, no treatment throughout; /+/, no treatment for 5 d, treated with BMP7 for 4 d, and no treatment thereafter; 
+/+/, treatment for 9 d and no treatment thereafter (n = 5). *, P < 0.001 versus //; #, P < 0.001 versus //. (F) CSCs were cultured in the 
presence (+/+), absence (/), or withdrawal after treatment (+/) of BMP7, and SA–-gal staining was performed (n = 6). ***, P < 0.001. Bar, 10 µm.  
(G and H) The CSCs were treated with BMP7, and the expression of NDRG1 (G) and p21 (H) was measured by qRT-PCR. /, no treatment control; +/+, 
continuous treatment with BMP7 for 96 h; +/, 48-h treatment followed by 48-h withdrawal of BMP7 (n = 3). *, P < 0.05; **, P < 0.01. (I) A similar ex-
periment was performed as in E for CSCs from PC3 mm/Tet-NDRG1 with (+) or without () induction of NDRG1, followed by assaying sphere formation. 
//, no induction throughout; /+/, no induction for 5 d, induction for 3 d, and no induction thereafter; +/+/, induction for 8 d and no treat-
ment thereafter (n = 5). *, P < 0.001 versus //; #, P < 0.001 versus //. (J) A similar experiment was performed as in F for CSCs from PC3 mm/
Tet-NDRG1. They were cultured with (+/+) or without (/) induction or withdrawal after induction of NDRG1 (+/), and SA–-gal staining was per-
formed (n = 8). ***, P < 0.001. The expression of NDRG1 and -tubulin was examined by Western Blot (top). The experiment in A was performed twice, 
experiments in B–J were performed three times independently, and representative data are shown. Results are shown as mean ± SEM.JEM Vol. 208, No. 13 
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Figure 8.  BMP7 suppresses tumor growth, but withdrawal induces tumor recurrence of CSCs in vivo. (A) CSCs isolated from PC3 mm were coin-
jected into tibiae of nude mice with control (scramble; n = 11) or BMP7–knocked down (shBMP7 #1, n = 14; #2, n = 10) HS5 cells. (left) BLI and x-ray radiog-
raphy of bone lesions from representative mice in each group 4 wk after inoculation. Osteolytic lesions are indicated by arrowheads. (middle) Normalized BLI 
signals after 4 wk. *, P < 0.05 by Mann-Whitney test. (right) Representative images of immunohistochemical staining of tumors in the tibiae for p-p38 and 
NDRG1. (B) CSCs isolated from PC3 mm/shNDRG1 (n = 12) or PC3 mm/scramble (n = 12) were coinjected with HS5 into tibiae of nude mice. (left) BLI and  
x-ray radiography of representative mice in each group 4 wk after inoculation. Osteolytic lesions are indicated by arrowheads. (middle) BLI after 4 wk. **, P < 
0.01 by Mann-Whitney test. (right) H&E staining of the tibiae from representative mice 4 wk after inoculation. The asterisk indicates a tumor. (C) Kaplan-
Meier bone metastasis–free survival curve of mice after intracardiac injection with CSCs isolated from PC3 mm (left) or C4-2B (right) followed by treatment 
with vehicle or BMP7. Control, control vehicle treatment (PC3 mm, n = 9; C4-2B, n = 10); BMP7, continuous treatment with BMP7 (PC3 mm, n = 15; C4-2B,  
n = 10); BMP7 withdrawal, BMP7 treatment (2 wk for PC3 mm and 3 wk for C4-2B) followed by withdrawal of BMP7 (PC3 mm, n = 9; C4-2B, n = 10). ***, P = 
0.0008; and **, P = 0.0012 versus control; and ###, P < 0.0001; and #, P = 0.0289 versus BMP7 by Log-rank test. (D) Effect of BMP7 on senescence was ex-
amined by SA–-gal staining. The bone derivatives of PC3 mm (PC3 mm–BM) were cultured with (+/+) or without (/) BMP7 for 96 h. +/ cells were 
treated with BMP7 for 48 h followed by withdrawal of BMP7 and further incubation for 48 h (n = 3). ***, P < 0.001. (E, top) After injection of CSCs into mouse 
tibiae, BMP7 was administered daily i.v. Control, control vehicle treatment (n = 13); BMP7, continuous treatment with BMP7 (n = 10); withdrawal, 10-d treat-
ment followed by withdrawal of BMP7 (n = 10). *, P < 0.05 versus control; ###, P < 0.001 versus BMP7 treatment. (bottom) Representative SA–-gal staining 
(blue-green) of tumors in the tibiae of mice at the end point. Experiments in A–C and E were performed twice, the experiment in D was performed three times 
independently, and representative data are shown. Results are shown as mean ± SEM. Bars: (A, D, and E) 50 µm; (B) 200 µm.2650 BMP7 in prostate cancer dormancy and recurrence | Kobayashi et al.
Similarly, another transcription factor Zeb1-mediated EMT 
has also been suggested to suppress cellular senescence (Liu   
et al., 2008). Therefore, this ability of BMP7 to counteract 
EMT may partly contribute to the BMP7-induced reversible 
senescence of the CSCs. Although BMP7 is expressed in a 
variety of normal tissues, aberrant expression of BMP7 in 
various epithelial tumors has also been reported (Mehler et al., 
1997; Bobinac et al., 2005; Hruska et al., 2005; Buijs et al., 
2007b). The results of expression analysis for BMP7 in prostate 
and breast cancers are contradictory depending on the reports, 
which suggests intricate roles of this gene in tumor progres-
sion, similar to the role of TGF- in tumorigenesis (Massagué, 
2008). However, it has recently been reported that BMP7 
expression in primary human prostate cancer tissue was 
strongly down-regulated compared with normal prostate   
epithelium and that ectopic expression of BMP7 in, or ex-
ogenous addition of BMP7 to, prostate cancer cell lines sig-
nificantly suppressed metastatic potential in vivo (Buijs et al., 
2007a; Morrisey 2010). Therefore, it is plausible that although 
BMP7 is necessary for the maintenance of normal differentia-
tion of prostate gland tissue, the loss of expression of this gene 
promotes EMT and metastatic ability of CSCs. Importantly, 
our study showed that BMP7 is expressed at a much higher 
level in the bone stromal cells than in the prostate cancer 
cells. When the tumor cells reach the distant organs, BMP7 
secreted in the microenvironment may again block EMT and 
promote differentiation of the tumor cells to become senes-
cent and dormant. In addition, our results indicate that BMP7 
also induced NDRG1, which was originally identified as a 
differentiation-related gene. However, questions still remain 
about what causes the change in BMP7 expression in clinical 
settings that allows the outgrowth of metastasis. One possible 
cause is aging as reported that the expression of BMP7 has been 
observed to be dramatically reduced in human articular cartilage 
during aging (Chubinskaya et al., 2002). Another possibility 
is that BMP7 expression is affected by androgen status, which 
is also associated with aging. The expression of BMP7 messen-
ger RNA was indeed shown to be increased by androgen and 
decreased after orchidectomy (Thomas et al., 1998). There-
fore, androgen ablation therapy as well as age-related decline 
in androgens may cause the change in expression of BMP7 
that allows the recurrent growth of dormant cancer cells.
BMP7 has been shown to induce bone formation in animal 
models and enhance bone repair in clinical studies (Sampath 
et al., 1992; Ripamonti et al., 1996; Friedlaender et al., 2001; 
Ristiniemi et al., 2007). Our in vivo studies showed that 
BMP7  treatment  inhibited  the  tumor-induced  osteolysis, 
suggesting that osteoinductive function of BMP7 may also 
contribute to the tumor suppression in the bone by counter-
acting the osteolytic activity of cancer cells. The processes of 
bone resorption and bone formation are almost always cou-
pled, and both resorption and formation have been shown   
to be activated in most bone metastases (Mundy, 2002).   
Although bone metastases of prostate cancer are frequently 
osteoblastic, 20–60% of patients have metastases that are os-
teolytic or mixed osteolytic and osteoblastic (Niell et al., 1983; 
To further verify the inhibitory effect of BMP7 in the bone, 
CSCs were inoculated directly into mouse tibiae followed   
by BMP7 treatment. We found that tumor growth in tibiae 
was indeed significantly suppressed by BMP7 treatment com-
pared with control (Fig. 8 E), suggesting that direct injection 
of BMP7 can block the growth of CSCs in the bone. More-
over, withdrawal of BMP7 treatment led the tumor to regain 
the ability to further proliferate in the bone. Of note, the   
tumor cells in tibiae exhibited features of cellular senescence 
during BMP7 treatment (Fig. 8 E, BMP7), whereas SA–-gal 
staining was strongly decreased after withdrawal of BMP7 
(Fig. 8 E, withdrawal). These results again suggest that BMP7 
plays a critical role in balancing the dormancy and recurrence 
of CSCs in bone metastasis of prostate cancer.
DISCUSSION
Recurrent disease is the most daunting issue for cancer pa-
tients because virtually no treatment option is available and it 
is almost always fatal. Clinically, tumor dormancy is defined 
as asymptomatic or having minimum residual disease after 
treatment (Aguirre-Ghiso, 2007). The disseminated cancer 
cells often undergo dormancy for years to decades before re-
currence; however, little is known about the underlying 
molecular mechanism of the pathological process, although 
several theories have been proposed, including balance of 
immunosurveillance, lack of angiogenesis, and induction of 
quiescence of tumor cells by microenvironmental factors 
(Aguirre-Ghiso, 2007; Steeg and Theodorescu, 2008). In this 
study, we have demonstrated that BMP7 secreted from bone 
stromal cells is capable of inducing senescence to the CSCs 
through activation of p38, p21, and NDRG1. Importantly, 
this senescence is reversible and the CSCs regain the ability 
to proliferate immediately upon withdrawal of BMP7 both 
in vitro culture and in our animal models. Consistent with 
these data, the expression of a BMP7 receptor, BMPR2, was 
found to have significant correlation with recurrence-free 
survival and significant inverse correlation with bone metas-
tasis of prostate cancer patients. Therefore, our results strongly 
suggest that BMP7 plays a critical role in tumor dormancy 
and recurrence, particularly in bone metastasis.
BMP7 belongs to the TGF- family, and it is involved   
in various functions of normal development including bone 
morphogenesis (Dudley et al., 1995; Friedlaender et al., 2001; 
Chen et al., 2004; Ristiniemi et al., 2007). Several lines of 
recent evidence suggest that BMP7 contributes to the inhibi-
tion of migration and invasion of cancer cells and this may   
be because of the ability of BMP7 to counteract epithelial–
mesenchymal transition (EMT), which is a hallmark of the 
aggressive tumor phenotype (Zeisberg et al., 2003; Buijs et al., 
2007a; Ye et al., 2007). We also found that BMP7 indeed up-
regulated the expression of epithelial genes such as E-cadherin, 
whereas it suppressed mesenchymal genes such as fibronec-
tin and vimentin in PC3 mm cells (unpublished data). In this 
context, it is noteworthy that EMT induced by Twist1 and/or 
Twist2 was shown to lead human epithelial cells to escape from 
oncogene-induced premature senescence (Ansieau et al., 2008). JEM Vol. 208, No. 13 
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function through both Smad-dependent and -independent 
pathways (Derynck and Zhang, 2003; Miyazono et al., 2010). 
In this study, we have shown that BMP7 induced senescence 
via a non-Smad pathway by activating p38 MAPK and p21. 
p38 is a bifunctional cell signaling molecule, and it is reported 
to both suppress and promote tumor cell proliferation in a 
context-dependent  manner  (Wagner  and  Nebreda,  2009). 
Interestingly, Ventura et al. (2007) recently reported that p38 
was capable of coordinating self-renewal and differentiation 
of the normal lung stem and progenitor cells and that inacti-
vation of p38 led to abnormal proliferation of lung epithelial 
cells followed by hypersensitivity to Kras-mediated tumor   
induction, suggesting an important tumor-suppressive role of 
p38 at an early stage of tumorigenesis. It should also be noted 
that p38-activating kinases, MKK4 and MKK6, have been 
shown to suppress metastasis of ovarian cancer, suggesting a 
diverse function of p38 in tumor progression (Hickson et al., 
2006). Recently, several lines of evidence suggest that the 
balance of p38 and ERK is a critical factor to determine the 
state of dormancy and proliferation in several types of tumor 
cells  (Aguirre-Ghiso  et  al.,  2003,  2004).  p38  was  indeed 
shown to be able to arrest cell cycle by up-regulating the key 
negative cell cycle regulator, p21, which is also activated dur-
ing cellular senescence (Han and Sun, 2007; Abbas and Dutta, 
2009). In contrast, ERK is a major positive cell cycle regula-
tor that is responsive to many extracellular mitotic stimuli by 
regulating G0–G1–S phase transition (Hoshino et al., 1999). 
How the balance of p38/ERK is controlled and what down-
stream signaling coordinates the direction to dormancy or   
recurrence are not yet clearly defined; however, our data in-
dicate that the level of BMP7 expression in the metastatic 
microenvironment  or  status  of  BMP  receptors  of  tumors 
plays a pivotal role in modulating p38 activation and in deter-
mining the fate of CSCs for dormancy and recurrence.
NDRG1 expression has been shown to be significantly 
down-regulated in a variety of carcinomas, including pros-
tate, breast, colon, pancreas, and esophageal squamous cell 
carcinomas (van Belzen et al., 1997; Bandyopadhyay et al., 
2003, 2004; Ando et al., 2006; Maruyama et al., 2006), and 
importantly, the expression of NDRG1 was shown to be   
inversely correlated with bone metastasis of prostate cancer   
patients (Bandyopadhyay et al., 2003). NDRG1 exerts both   
tumor-suppressor and metastasis-suppressor activities in a cell 
context–dependent fashion, and we indeed previously showed 
that NDRG1 was capable of directly suppressing metastasis 
without affecting the primary tumor growth in an animal 
model of prostate cancer (Bandyopadhyay et al., 2003). In this 
study, we demonstrated that NDRG1 was able to induce re-
versible cellular senescence in a p38- and p21-dependent 
manner in CSCs. Our results also indicate that the up-regulation 
of NDRG1 by BMP7 is mediated by p21. p21 has been 
shown to directly bind to c-Myc, E2F1, and STAT3 and in-
hibit their transcriptional activity (Kitaura et al., 2000; Abbas 
and Dutta, 2009). Importantly, both c-Myc and N-Myc have 
been shown to suppress NDRG1 expression (Li and Kretzner, 
2003; Ellen et al., 2008). Therefore, NDRG1 activation by 
Shimazaki et al., 1992; Cheville et al., 2002). Furthermore, it 
has been reported that the course of bone lesions showed a 
tendency to change from the osteolytic to osteoblastic type 
and relapse was often accompanied by an increase in the os-
teolytic type lesion (Shimazaki et al., 1992), suggesting that 
osteolysis plays an important role in bone metastases of pros-
tate cancer. Interestingly, androgen ablation, which is a stan-
dard treatment for prostate cancer, has been shown to increase 
osteoclastic bone resorption and bone loss (Smith et al., 2001, 
2005; Guise et al., 2006). This excess fracture risk associated 
with hormone therapy may be related to the development of 
bone metastases of prostate cancer.
Cellular senescence is generally viewed as an irreversible 
process and considered to serve as a barrier against tumori-
genesis and metastasis; however, in this study, we have shown 
that BMP7 reversibly induced senescence and blocked prolif-
eration of CSCs. The reversibility of senescence has been 
shown in several normal cells. Sage et al. (2003) previously 
reported that acute loss of retinoblastoma tumor suppressor 
reversed senescence in mouse embryonic fibroblasts, and they 
also showed that Ras oncogene–induced senescence was re-
versed by the loss of retinoblastoma. In addition, inactivation 
of tumor suppressor, p53, was also shown to reverse replica-
tive senescence in mouse embryonic fibroblasts and human 
fibroblasts  (Beauséjour  et  al.,  2003;  Dirac  and  Bernards, 
2003). More recently, reactive oxygen species–induced se-
nescence in primary human fibroblast was found to be re-
versed by knockdown of PLA2R (phospholipase A2 receptor; 
Augert et al., 2009). To our knowledge, our result is the first 
study to show the reversibility of senescence in CSCs, and we 
are proposing that BMP7-induced reversible senescence is at 
least a part of the underlying mechanism of tumor cell dor-
mancy and recurrence. Therefore, it is conceivable that loss   
of BMP7 receptors may serve as one of the mechanisms for 
metastatic cells to escape from dormancy and promote meta-
static recurrence. We indeed found that expression of BMPR2, 
one of the BMP7 receptors, was significantly correlated with 
recurrence-free survival and inversely correlated with bone 
metastasis of prostate cancer patients. We have also shown 
that when BMPR2 was knocked down in prostate cancer 
cells, they became irresponsive to activation of p38 signaling 
and to concomitant induction of senescence in vitro. In sup-
port of our hypothesis, BMPR2 expression was also found   
to be frequently lost in aggressive bladder and colon cancers 
(Kim et al., 2004; Kodach et al., 2008a,b). Therefore, the 
BMP7-BMPR2 signaling is considered to play a critical role 
in metastatic tumor growth and dormancy.
Because the self-renewal of CSCs requires an appropriate 
niche at the metastasized site that provides specific growth-
promoting factors, recurrent growth of such dormant cells is 
likely to be triggered by stem cell–related pathways such as 
Wnt, Notch, and Hedgehog (Visvader and Lindeman, 2008; 
Rosen and Jordan, 2009). Understanding the signaling pathway 
of BMP7-induced dormancy is an intriguing question, and 
elucidating the cross talk mechanism with recurrent signaling   
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Western blot. The cells were lysed and analyzed by immunoblotting using   
antibodies specific for the following proteins: total and phospho-p38, p21, 
p27 (Cell Signaling Technology), NDRG1 (gift from T. Commes, Univer-
sité de Montpellier 2, Montpellier, France), BMP7, BMPR2 (R&D Sys-
tems), and -tubulin (Millipore).
Sphere-forming  assay.  CSCs  were  plated  (500  cells/ml)  in  ultra-low   
attachment plates (Corning) with DME/F12 supplemented with 2% B27 
(Invitrogen), 20 ng/ml EGF (Sigma-Aldrich), and 4 µg/ml insulin (Sigma-
Aldrich). They were then incubated with or without 200 ng/ml BMP7 or 
tetracycline as described in the legend for Fig. 7 (E and I). The number of 
prostaspheres was counted, and data were represented as the means ± SEM.
Reporter  assay.  The  promoter  plasmids  of  pGL3-NDRG1  (promoter   
region 1,433 to 97) and p21 (WWP-luciferase; a gift from B. Vogelstain, 
Howard Hughes Medical Institute, Baltimore, MD) were used. They were 
transfected to PC3 mm using Lipofectamine, and cells were cultured with or 
without BMP7 or CM for 48 h and subjected to reporter assay. Luciferase 
activities were measured by using the Dual-Luciferase Reporter Assay   
System  (Promega)  and  Luminometer  (Berthold  Detection  Systems).  For 
each experiment, the Renilla expression plasmid, phRG-TK (Promega), was 
cotransfected as an internal control, and the promoter activities were nor-
malized accordingly.
Quantitative  RT-PCR  (qRT-PCR)  analysis. Total RNA was isolated 
from the cells and reverse transcribed. The cDNA was then amplified with 
a pair of forward and reverse primers for the following genes: NDRG1 
(5-CGCTGAGGTGAAGCCTTTGG-3 and 5-GGTTCATGCCGAT-
GTCATGG-3),  p21  (5-GGAAGACCATGTGGACCTGTC-3  and 
5-CGGATTAGGGCTTCCTCTTGG-3), BMP7 (5-GATCTCTTCCT-
GCTCGACAG-3 and 5-CAACTTGGGGTTGATGCTCTG-3), BMPR2 
(5-CCAAGAGTGTCACTATGAAG-3 and 5-TGAATGAGGTGGA-
CTGAGTG-3),  and  -actin  (5-TGAGACCTTCAACACCCCAGC-
CATG-3 and 5-CGTAGATGGGCACAGTGTGGGTG-3). The thermal 
cycling conditions composed of an initial denaturation step at 95°C for   
1 min followed by 35 cycles of PCR using the following profile: 94°C for   
30 s, 58°C for 30 s, and 72°C for 30 s.
In situ apoptosis assay. PC3 mm cells were cultured in the presence of 
CM of HS5 or MCF7 for 48 h and fixed with 4% paraformaldehyde in 
PBS followed by permeabilization with 0.2% Triton-X 100/0.1% sodium 
citrate at 4°C. The cells were then washed extensively, and terminal de-
oxynucleotidyl transferase-mediated dUTP-biotin end labeling assay was 
performed using the In Situ Cell Death Detection kit/TMR Red (Roche). 
The reaction was stopped after 1 h, and the number of apoptotic cells in 
each  well  was  counted  under  an  SP5  spectral  laser-scanning  confocal   
microscope (Leica).
Animal experiments. All animal work was performed in accordance with 
a protocol approved by the Laboratory Animal Care and Use Committee   
of Southern Illinois University School of Medicine. Athymic nude mice 
(Harlan) with the ages of 4–5 and 7–8 wk were used for tumorigenic ability 
assay and other xenograft experiments, respectively. For tumorigenic ability 
assay, 102, 103, or 104 cells were injected subcutaneously into the mice, and 
primary  tumor growth  was  monitored weekly  by  BLI. For  intraosseous   
inoculation, 2 × 104 CSCs with or without 2 × 104 bone stromal cells were 
injected into the tibiae of the mice. For recurrence assay, 100 µg/kg BMP7 
or vehicle alone was subsequently injected daily into the tail vein. For me-
tastasis experiments, 105 CSCs isolated from PC3 mm cells, 106 CSCs iso-
lated from C4-2B cells, or 5 × 105 PC3 mm/shBMPR2 or PC3 mm/scramble 
cells were injected into the left cardiac ventricle of the mice. To obtain bone 
derivatives  of  PC3  mm  CSCs  in  micrometastases,  105  GFP/luciferase- 
expressing cells were injected into the left cardiac ventricle of the mice. 4 wk 
after the injection, metastasized cells in tibiae were flashed with a 26-guage 
needle,  and  GFP-positive  cells  were  sorted.  Several  independent  bone   
BMP7 is likely to be mediated by inhibition of c-Myc by 
p21, although this possibility needs to be further tested. These 
results suggest that BMP7 induces cellular senescence in CSCs 
by activating NDRG1 via the p38 signaling pathway fol-
lowed by mobilizing the intrinsic transcriptional network, 
which eventually leads to tumor dormancy.
The ultimate goal of treating patients with dormant 
tumors is to eradicate the residual cancer cells that are be-
lieved to be the cancer stem cells; however, confining such 
cells in the state of perpetual dormancy is another rational 
approach. Considering that the BMP7–p38–NDRG1 axis 
induces growth arrest of prostate CSCs, as we reported in 
this study, and given that BMP7 is already FDA approved 
for clinical use to heal bone fractures, BMP7 or a small 
molecule that mimics its function may serve as a potential 
antirecurrence agent to treat cancer patients with meta-
static disease.
MATERIALS AND METHODS
Cell culture. PC3 mm was provided by I.J. Fidler (The University of Texas   
MD  Anderson  Cancer  Center,  Houston, TX).  DU145,  HS5,  NIH3T3, 
MRC5, and hFOB1.19 were obtained from the American Type Culture 
Collection. ALVA41  was  provided  by W.  Rosner  (Columbia  University, 
New York, NY). LNCaP, C4, C4-2, and C4-2B were obtained from the   
University of Texas MD Anderson Cancer Center. The PC3 mm/Tet-NDRG1   
cell line was established as previously described (Bandyopadhyay et al., 2006). 
hBMSCs were isolated from human BM (Lonza) by depletion of red blood 
cells followed by enrichment of plastic adherent cells. The MSC popula-
tion was characterized by flow cytometry for expression of negative (CD34 
and  CD45)  and  positive  (CD44  and  CD29)  surface  markers,  and  their 
multipotent potential was confirmed by the capacity to differentiate into 
adipogenic and osteogenic lineages. hBMSCs were maintained in minimum   
essential medium with 20% fetal bovine serum, 100 µg/ml streptomycin, and 
100 U/ml penicillin. hFOB1.19 was cultured in 1:1 DME medium/Ham’s 
F12  medium  without  phenol  red  supplemented  with  10%  fetal  bovine   
serum, 100 µg/ml streptomycin, and 100 U/ml penicillin at 34°C, and it 
was differentiated into mature phenotype at 39°C for 24 h. Other cells were 
grown in RPMI 1640 medium with 10% fetal bovine serum, 100 µg/ml 
streptomycin, and 100 U/ml penicillin, and they were grown at 37°C in a 
5% CO2 atmosphere. For bioluminescent tracking, cell lines were lentivirally 
transduced with firefly luciferase. shRNA-expressing lentiviral plasmids car-
rying puromycin selection markers for BMP7, p21, NDRG1, and BMPR2 
were obtained from Thermo Fisher Scientific. The tetracycline-inducible 
shRNA knockdown was achieved using the Tet-pLKO system (Addgene 
plasmid 21915; Wiederschain et al., 2009) by targeting the sequence 5-GCCT-
ATGGAGTGAAATTATTTCTCGAGAAATAATTTCACTCCATAGGC-3  
for BMPR2. Recombinant human BMP4, BMP5, BMP6, and BMP7 were 
purchased  from  ProSpec.  Recombinant  human  BMP2  and  FGF2  were 
obtained from GenWay Biotech, Inc. Recombinant human Noggin was 
purchased from R&D Systems. Recombinant human TGF- was obtained 
from Pathtech. SB203580 and SB431542 were purchased from Sigma- 
Aldrich.  The  dominant-negative  mutant  of  Smad4  was  a  gift  from   
M.P. Decaestecker (Vanderbilt University, Nashville, TN).
Isolation of CSCs. CSCs were isolated by magnetic bead sorting using a 
MACS Separator (Miltenyi Biotec). PC3 mm or C4-2B cells were incubated 
with specific antibodies as follows: anti-CD24-biotin (STEMCELL Tech-
nologies), anti-CD44-APC (BioLegend), and anti-CD133-biotin (Miltenyi 
Biotec). CD24/CD44+/CD133+ cells were then enriched by using a MACS 
magnet and MS columns (Miltenyi Biotec). All MACS procedures were 
performed according to the manufacturer’s instructions.JEM Vol. 208, No. 13 
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